🇺🇸 FDA

Intelligence · Clinical Pipeline

R&D Pipeline Programs

ClinicalTrials.gov programs linked to pharma sponsors — phase, modality, and trial IDs for BD and competitive intelligence.

Programs indexed
20,548
Companies
1,769
Drugs tracked
4,797

Quick answer

NovaPharmaNews tracks 20,548 pharmaceutical R&D pipeline programs sourced from ClinicalTrials.gov, linked to sponsor companies. Each profile includes development phase, modality, trial status, NCT identifiers, and indication text — searchable for business development and competitive intelligence.

951 results for “Eli” Clear

  1. Tirzepatide

    Eli Lilly and Company

    Metabolic Dysfunction-Associated Steatotic Liver Disease

    phase 3 small molecule active

    1 trial

  2. Tirzepatide, Tirzepatide, Tirzepatide, Tirzepatide, Mirikizumab, Mirikizumab, to match Tirzepatide, Tirzepatide, Mirikizumab, Tirzepatide

    Eli Lilly Co.

    Obesity or Overweight, Crohn’s Disease

    phase 3 small molecule active

    1 trial

  3. Tirzepatide, Tirzepatide, Tirzepatide, Tirzepatide, Tirzepatide, Tirzepatide, Placebo to match LY3298176 injection

    Eli Lilly Co.

    Obesity

    phase 3 small molecule active

    1 trial

  4. Tislelizumab

    BeiGene

    Recurrent or Metastatic Nasopharyngeal Cancer

    phase 3 small molecule completed

    1 trial

  5. Tislelizumab

    BEONE MEDICINES AUS PTY LTD

    Esophageal Squamous Cell Carcinoma (ESCC)

    phase 3 small molecule completed

    1 trial

  6. Tislelizumab

    BeiGene

    Non-small Cell Lung Cancer

    phase 3 small molecule completed

    2 trials

  7. Tislelizumab

    BEONE MEDICINES AUS PTY LTD

    Urothelial Carcinoma

    phase 3 small molecule active

    1 trial

  8. Tislelizumab

    BEONE MEDICINES AUS PTY LTD

    Advanced Malignancies

    phase 3 small molecule active

    1 trial

  9. Tislelizumab

    Xiyuan Hospital of China Academy of Chinese Medical Sciences

    Colonic Neoplasms

    phase 3 small molecule active

    1 trial

  10. Tislelizumab

    BEONE MEDICINES AUS PTY LTD

    Non Small Cell Lung Cancer

    phase 3 small molecule active

    4 trials

  11. Tislelizumab

    BEONE MEDICINES AUS PTY LTD

    Classical Hodgkin Lymphoma

    phase 3 small molecule terminated

    1 trial

  12. Tislelizumab

    The First People's Hospital of Lianyungang

    Rectal Neoplasms

    phase 3 small molecule active

    1 trial

  13. Tislelizumab

    Xiyuan Hospital of China Academy of Chinese Medical Sciences

    Locally Advanced Rectal Carcinoma

    phase 3 small molecule active

    1 trial

  14. Tislelizumab + SOX Chemotherapy

    The First People's Hospital of Lianyungang

    Gastric Cancer Stage III

    phase 3 small molecule active

    1 trial

  15. Tislelizumab 300 mg solution for injection, Tevimbra 100 mg concentrate for solution for infusion

    BEONE MEDICINES AUS PTY LTD

    Locally advanced unresectable or metastatic gastric or gastroesophageal junction adenocarcinoma

    phase 3 small molecule active

    1 trial

  16. Tislelizumab（neoadjuvant）

    Xiyuan Hospital of China Academy of Chinese Medical Sciences

    Head and Neck Squamous Cell Carcinomas

    phase 3 small molecule active

    1 trial

  17. Tocilizumab, Placebo to match 2 mg/mL oral suspension, BARICITINIB, Baricitinib, Placebo to match 4 mg tablet, TOCILIZUMAB , Placebo to match 2 mg tablet, JAK1/JAK2 inhibitor, Placebo to match 1 mg tablet, BARICITINIB

    Eli Lilly Co.

    Systemic Juvenile Idiopathic Arthritis

    phase 3 small molecule active

    1 trial

  18. Tremelimumab

    AstraZeneca

    Hepatocellular Carcinoma

    phase 3 small molecule active

    1 trial

  19. Triptorelin for Injection

    The First People's Hospital of Lianyungang

    Ovarian Hyperstimulation Syndrome

    phase 3 small molecule active

    1 trial

  20. UGN-104

    Lacuna Pharma Pty Ltd

    Low-grade Upper Tract Urothelial Cancer

    phase 3 small molecule active

    1 trial

  21. Ultomiris 300 mg/3 mL concentrate for solution for infusion

    Alexion Europe SAS

    Neuromyelitis Optica Spectrum Disorder (NMOSD)

    phase 3 small molecule active

    1 trial

  22. Veligrotug

    Viridian Pharma Ltd

    Thyroid Eye Disease

    phase 3 small molecule completed

    1 trial

  23. Veligrotug (VRDN-001)

    Viridian Pharma Ltd

    Thyroid Eye Disease

    phase 3 small molecule completed

    1 trial

  24. Venclyxto 100 mg film-coated tablets, Levact 2,5 mg/ml poudre pour solution à diluer pour perfusion, BGB-16673, BGB-16673, Venclyxto 10 mg film-coated tablets, Venclyxto 50 mg film-coated tablets, MabThera 500 mg concentrate for solution for infusion, MabThera 100 mg concentrate for solution for infusion, Zydelig 150 mg film-coated tablets, Zydelig 100 mg film-coated tablets

    BEONE MEDICINES AUS PTY LTD

    Chronic lymphotic leukemia and Small Lymphocytic lymphoma

    phase 3 small molecule active

    1 trial

Frequently asked questions

What is the NovaPharmaNews pipeline directory?

It is a searchable index of 20,548 clinical development programs grouped by sponsor company, with phase (Phase 1–3), modality, trial status, and linked NCT IDs from ClinicalTrials.gov.

Where does pipeline data come from?

Program records are derived from ClinicalTrials.gov and linked to NovaPharmaNews company profiles. Trial status and phase reflect registry data at last sync — verify on ClinicalTrials.gov before investment or partnering decisions. See our data sources page for attribution.

How do I find pipeline programs by company or phase?

Use the search box to match program name, indication, company name, or slug. Results are ordered with late-stage (Phase 3) programs first. Open any row to view the full program profile under its sponsor company.

Data attribution and licensing: Data sources